{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T15:49:53Z","timestamp":1792597793316,"version":"4.5.0"},"reference-count":25,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinical-breast-cancer.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Breast Cancer"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1016\/j.clbc.2025.05.012","type":"journal-article","created":{"date-parts":[[2025,5,26]],"date-time":"2025-05-26T02:03:38Z","timestamp":1748225018000},"page":"e990-e1000.e2","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Decrease in Calcifications After Neoadjuvant Treatment Predicts Invasive Tumor Response but Not Complete DCIS Eradication: Systematic Review and Meta-Analysis"],"prefix":"10.1016","volume":"25","author":[{"ORCID":"https:\/\/orcid.org\/0009-0001-9103-0955","authenticated-orcid":false,"given":"Noam","family":"Weiner","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yaron","family":"Niv","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eran","family":"Sharon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clbc.2025.05.012_bib0001","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1023\/A:1008400706949","article-title":"A reduction in the requirements for mastectomy in a randomized trial of neoadjuvant chemoendocrine therapy in primary breast cancer","volume":"9","author":"Makris","year":"1998","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clbc.2025.05.012_bib0002","doi-asserted-by":"crossref","first-page":"S125","DOI":"10.1016\/j.jacr.2023.02.016","article-title":"ACR Appropriateness Criteria\u00ae monitoring response to neoadjuvant systemic therapy for breast cancer: 2022 update","volume":"20","author":"JH","year":"2023","journal-title":"J Am Coll Radiol"},{"key":"10.1016\/j.clbc.2025.05.012_bib0003","doi-asserted-by":"crossref","first-page":"2147","DOI":"10.1056\/NEJMoa1612645","article-title":"Adjuvant capecitabine for breast cancer after preoperative chemotherapy","volume":"376","author":"Masuda","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clbc.2025.05.012_bib0004","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1056\/NEJMoa1814017","article-title":"KATHERINE Investigators. Trastuzumab emtansine for residual invasive HER2-positive breast cancer","volume":"380","author":"von Minckwitz","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clbc.2025.05.012_bib0005","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1200\/JCO.20.03399","article-title":"Neoadjuvant chemotherapy, endocrine therapy, and targeted therapy for breast cancer: ASCO guideline","volume":"39","author":"Korde","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clbc.2025.05.012_bib0006","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.2214\/ajr.179.5.1791193","article-title":"Accuracy of MR imaging for revealing residual breast cancer in patients who have undergone neoadjuvant chemotherapy","volume":"179","author":"Partridge","year":"2002","journal-title":"AJR Am J Roentgenol"},{"key":"10.1016\/j.clbc.2025.05.012_bib0007","article-title":"Breast cancer surgery: current standards and strategies","author":"Gatzemeier","year":"2021","journal-title":"ESMO Preceptorship Breast Can"},{"key":"10.1016\/j.clbc.2025.05.012_bib0008","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1093\/ptj\/89.9.873","article-title":"PRISMA Group. Reprint\u2013preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement","volume":"89","author":"Moher","year":"2009","journal-title":"Phys Ther"},{"key":"10.1016\/j.clbc.2025.05.012_bib0009","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1002\/jrsm.12","article-title":"A basic introduction to fixed-effect and random-effects models for meta-analysis","volume":"1","author":"Borenstein","year":"2010","journal-title":"Res Synth Methods"},{"key":"10.1016\/j.clbc.2025.05.012_bib0010","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1136\/bmj.315.7109.629","article-title":"Bias in meta-analysis detected by a simple, graphical test","volume":"315","author":"Egger","year":"1997","journal-title":"BMJ"},{"key":"10.1016\/j.clbc.2025.05.012_bib0011","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1046\/j.1445-2197.2003.02748.x","article-title":"Methodological index for non-randomized studies (minors): development and validation of a new instrument","volume":"73","author":"Slim","year":"2003","journal-title":"ANZ J Surg"},{"key":"10.1016\/j.clbc.2025.05.012_bib0012","article-title":"The role of mammographic calcification in the neoadjuvant therapy of breast cancer imaging evaluation","volume":"9","author":"Li","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.clbc.2025.05.012_bib0013","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1245\/s10434-014-4113-8","article-title":"Histopathologic correlation of residual mammographic calcifications after neoadjuvant chemotherapy for locally advanced breast cancer","volume":"22","author":"Adrada","year":"2015","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.clbc.2025.05.012_bib0014","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1016\/j.crad.2016.01.009","article-title":"Does change in calcifications with neoadjuvant treatment correlate with pathological tumour response?","volume":"71","author":"Golan","year":"2016","journal-title":"Clin Radiol"},{"key":"10.1016\/j.clbc.2025.05.012_bib0015","doi-asserted-by":"crossref","first-page":"1492","DOI":"10.1245\/s10434-016-5741-y","article-title":"Do calcifications seen on mammography after neoadjuvant chemotherapy for breast cancer always need to be excised?","volume":"24","author":"Feliciano","year":"2017","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.clbc.2025.05.012_bib0016","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1177\/0284185118776491","article-title":"Change in calcifications on mammography after neoadjuvant chemotherapy in breast cancer patients: correlation with tumor response grade and comparison with lesion extent","volume":"60","author":"Yim","year":"2019","journal-title":"Acta Radiol"},{"key":"10.1016\/j.clbc.2025.05.012_bib0017","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.ejrad.2019.06.017","article-title":"Complete response on MR imaging after neoadjuvant chemotherapy in breast cancer patients: factors of radiologic-pathologic discordance","volume":"118","author":"Choi","year":"2019","journal-title":"Eur J Radiol"},{"key":"10.1016\/j.clbc.2025.05.012_bib0018","doi-asserted-by":"crossref","first-page":"e82","DOI":"10.1016\/j.clbc.2019.05.015","article-title":"Do decreased breast calcifications after neoadjuvant chemotherapy predict pathologic complete response?","volume":"20","author":"Fushimi","year":"2019","journal-title":"Clin Breast Cancer"},{"key":"10.1016\/j.clbc.2025.05.012_bib0019","doi-asserted-by":"crossref","first-page":"5593","DOI":"10.21037\/qims-22-1170","article-title":"Value of mammographic calcifications and MRI-enhanced lesions in the evaluation of residual disease after neoadjuvant therapy for breast cancer","volume":"13","author":"Zhu","year":"2023","journal-title":"Quant Imaging Med Surg"},{"key":"10.1016\/j.clbc.2025.05.012_bib0020","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1186\/s12905-024-02973-9","article-title":"Impact of residual microcalcifcations on prognosis after neoadjuvant chemotherapy in breast cancer patients","volume":"24","author":"Kim","year":"2024","journal-title":"BMC Womens Health"},{"issue":"4","key":"10.1016\/j.clbc.2025.05.012_bib0021","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1097\/SLA.0000000000000924","article-title":"Tumor biology correlates with rates of breast-conserving surgery and pathologic complete response after neoadjuvant chemotherapy for breast cancer: findings from the ACOSOG Z1071 (Alliance) Prospective Multicenter Clinical Trial","volume":"260","author":"Boughey","year":"2014","journal-title":"Ann Surg"},{"issue":"9","key":"10.1016\/j.clbc.2025.05.012_bib0022","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1056\/NEJMoa1910549","article-title":"Pembrolizumab for early triple-negative breast cancer","volume":"382","author":"Schmid","year":"2020","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.clbc.2025.05.012_bib0023","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.4143\/crt.2021.901","article-title":"Real world evidence of neoadjuvant Docetaxel\/Carboplatin\/Trastuzumab\/Pertuzumab (TCHP) in patients with HER2-positive early or locally advanced breast cancer: a single-institutional clinical experience","volume":"54","author":"Kim","year":"2022","journal-title":"Cancer Res Treat"},{"issue":"4","key":"10.1016\/j.clbc.2025.05.012_bib0024","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/j.clbc.2016.12.010","article-title":"Role of Magnetic resonance imaging in detection of pathologic complete remission in breast cancer patients treated with neoadjuvant chemotherapy: a meta-analysis","volume":"17","author":"Gu","year":"2017","journal-title":"Clin Breast Cancer"},{"key":"10.1016\/j.clbc.2025.05.012_bib0025","doi-asserted-by":"crossref","DOI":"10.1016\/j.suronc.2023.102011","article-title":"The accuracy of MRI in detecting pathological complete response following neoadjuvant chemotherapy in different breast cancer subtypes","volume":"51","author":"Kuzmova","year":"2023","journal-title":"Surg Oncol"}],"container-title":["Clinical Breast Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1526820925001430?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1526820925001430?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,17]],"date-time":"2025-09-17T00:18:15Z","timestamp":1758068295000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1526820925001430"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10]]},"references-count":25,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2025,10]]}},"alternative-id":["S1526820925001430"],"URL":"https:\/\/doi.org\/10.1016\/j.clbc.2025.05.012","relation":{},"ISSN":["1526-8209"],"issn-type":[{"value":"1526-8209","type":"print"}],"subject":[],"published":{"date-parts":[[2025,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Decrease in Calcifications After Neoadjuvant Treatment Predicts Invasive Tumor Response but Not Complete DCIS Eradication: Systematic Review and Meta-Analysis","name":"articletitle","label":"Article Title"},{"value":"Clinical Breast Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clbc.2025.05.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}